Neuroendocrine Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (1 March 2021) | Viewed by 235
Special Issue Editor
Interests: neuroendocrine cancers; personalized cancer therapy; mouse models of neuroendocrine cancers; targeted drug delivery; nanomedicines; the tumor suppressor role of Notch
Special Issue Information
Dear Colleagues,
This Special Issue, “Neuroendocrine Cancers”, will focus on novel methods of the diagnosis, treatment and management of neuroendocrine neoplasms.
Neuroendocrine cancers are a heterogenous group of tumors originating in various locations, including the gastrointestinal tract, pancreas, lung, and thyroid gland. Surgical resection alone is often curative in early stages of the disease with localized tumors, but most neuroendocrine cancer patients are metastatic at the time of initial diagnosis. Patients with untreated, isolated neuroendocrine liver metastases have a <30% 5-year survival. It is reported that in the United States, there are in excess of 100,000 patients living with NE cancers, 16,000 new diagnoses each year, and more than 200,000 undiagnosed cases estimated. Almost 50% of patients with neuroendocrine cancer visit a doctor five or more times before receiving their diagnosis.
Furthermore, patients with liver metastases from neuroendocrine cancers often have debilitating symptoms, such as uncontrollable diarrhea, flushing and heart failure, due to the excessive hormone secretion that characterizes these tumors. Thus, it is imperative to develop new strategies for the diagnosis, treatment and management of neuroendocrine cancers.
We invite scientists in the field of neuroendocrine cancers to submit original research or review articles to this Special Issue of “Biomedicines”.
Dr. Renata Jaskula-Sztul
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine cancers
- targeted neuroendocrine cancer therapy
- in vivo and ex vivo models
- neuroendocrine cancer prognostic markers
- new neuroendocrine cancer markers
- small molecule compounds
- theranostics for neuroendocrine cancers
